Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Dollar and Under Sleeper Stocks -- Ignore unavailable to you. Want to Upgrade?

To: Timewalker who wrote (6658)	5/6/1998 4:35:00 PM
From: Logistics	Read Replies (1) \| Respond to of 8835

Late Breaking News: Re: MTCH Meditech Introduces Product For Treatment of Herpes SCOTTSDALE, Ariz., May 6 /PRNewswire/ -- Meditech Pharmaceuticals Inc. (OTC Bulletin Board: MTCH - news),is planning to introduce an over-the-counter, topical version on its compound, MTCH-24 for the treatment of Herpes Simplex I (cold sores). The company believes that its product is consistent with existing monographs for cold sore medications. Management believes that the MTCH-24 product is superior to any of the competitive OTC products now available for this use. A facility has been identified which is capable of manufacturing the MTCH-24 and could handle the Company's production requirements on a short to mid term basis. Management has had discussions with a marketing group which is ready to telemarket the product to thousands of independent drug and convenience stores as well as with an internet group prepared to handle retail sales direct to the consumer. Profit margins are expected be substantial enough to support a national retail introduction of MTCH-24 if this lead market is successful. The company plans to sell its product through the same channels as other similar products such a Colgate-Palmolive (NYSE: CL - news) and Zila Inc., (Nasdaq: ZILA - news) which involve retail chain drug stores and various mass merchandisers. The launch of the product is dependent upon the Company's ability to finance the product introduction. Management is optimistic that this can be accomplished in 1998 providing financing is available. Meditech's future results of operation and other forward looking statements contained in this document involve a number of risks and uncertainties. Factors which could cause results to differ materially are the following: business conditions and the general economy, competitive activity, and failure to achieve necessary funding support. Meditech Pharmaceuticals, Inc. (Meditech or the Company) is a publicly traded company, focusing in the areas of research, development, and marketing in the biomedical industry. Meditech's R & D efforts are concentrated in the area of anti-viral and anti-microbial drugs for ethical, over-the-counter, veterinary, and agricultural use. The Company was organized in 1983. SOURCE: Meditech Pharmaceuticals, Inc. ------------------------------------------------------------------------ More Quotes and News